Exploitation of the synthetic lethal relationship between defects in BRCA1 and BRCA2 tumour suppressors and with RAD52 depletion or inhibition (15–18,20,59,60) has opened many new questions into the role of the RAD52 protein in genome maintenance. The gene discussed is BRCA1; the disease is neoplasm.